Poly(D, L-lactide-co-glycolide)/montmorillonite nanoparticles for improved oral delivery of exemestane

The aim of this study was to develop poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles formulations for improved oral delivery of exemestane. Exemestane-loaded PLGA nanoparticles and PLGA/MMT nanoparticles were prepared by a modified solvent extraction/evaporation technology with vitamin E succinated polyethylene glycol 1000 (TPGS) as emulsifier. The content of MMT was estimated by thermal gravimetric analysis. The drug encapsulation efficiency and in vitro drug release kinetics were measured by high-performance liquid chromatography. The size, size distribution, surface charge and morphology of the exemestane-loaded nanoparticles were characterized using a Zetasizer Nano ZS and field emission scanning electron microscopy. The physical status of exemestane in the nanoparticles was characterized by differential scanning calorimetry. In vitro cellular uptake of coumarin-6-loaded nanoparticles was investigated by confocal laser scanning microscope, demonstrating that the fluorescence nanoparticles were internalized by Caco-2 cells (as an in vitro gastrointestinal model). The results of in vitro cytotoxicity experiment on MCF-7 cells (as a model of breast cancer cells) showed the exemestane-loaded nanoparticles resulted in lower cell viability versus the pure exemestane solution. The cytotoxicity against MCF-7 cells for exemestane-loaded nanoparticles and pure exemestane solution was dependent on the drug concentration and incubation time. In conclusion, this study indicates the capability of PLGA nanoparticles and PLGA/MMT nanoparticles in enhancing the oral delivery of exemestane.

[1]  Si-Shen Feng,et al.  Vitamin E TPGS as a molecular biomaterial for drug delivery. , 2012, Biomaterials.

[2]  Sanyog Jain,et al.  Solid lipid nanoparticles: an oral bioavailability enhancer vehicle , 2011, Expert opinion on drug delivery.

[3]  Raju Jukanti,et al.  Enhanced bioavailability of exemestane via proliposomes based transdermal delivery. , 2011, Journal of pharmaceutical sciences.

[4]  M. A. Holgado,et al.  Possibilities of poly(D,L-lactide-co-glycolide) in the formulation of nanomedicines against cancer. , 2011, Current drug targets.

[5]  S. Sahoo,et al.  PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. , 2011, Advanced drug delivery reviews.

[6]  M. Masserini,et al.  Cellular uptake of coumarin-6 as a model drug loaded in solid lipid nanoparticles. , 2011, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[7]  Wenming Liu,et al.  Folate-decorated hybrid polymeric nanoparticles for chemically and physically combined paclitaxel loading and targeted delivery. , 2011, Biomacromolecules.

[8]  I. Vural,et al.  Alternative oral exemestane formulation: improved dissolution and permeation. , 2010, International journal of pharmaceutics.

[9]  G. Bertelli,et al.  Exemestane in postmenopausal women with early or advanced breast cancer: a review , 2010, Expert opinion on pharmacotherapy.

[10]  Y. Miyoshi,et al.  Prediction of hormone sensitivity for breast cancers , 2010, Breast cancer.

[11]  J. Błasiak,et al.  How to study dendriplexes II: Transfection and cytotoxicity. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[12]  Gautam Mishra,et al.  Oral Bioavailability Enhancement of Exemestane from Self-Microemulsifying Drug Delivery System (SMEDDS) , 2009, AAPS PharmSciTech.

[13]  Chee Wee Gan,et al.  Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel. , 2009, Biomaterials.

[14]  D. Lake,et al.  Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer , 2008, Breast Cancer Research and Treatment.

[15]  Jie Pan,et al.  Targeted delivery of paclitaxel using folate-decorated poly(lactide)-vitamin E TPGS nanoparticles. , 2008, Biomaterials.

[16]  J. Nabholtz.  Long-term safety of aromatase inhibitors in the treatment of breast cancer , 2008, Therapeutics and clinical risk management.

[17]  Balu Ranganathan,et al.  Multifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer. , 2008, Biomaterials.

[18]  S. Feng,et al.  In vitro and in vivo studies on vitamin E TPGS-emulsified poly(D,L-lactic-co-glycolic acid) nanoparticles for paclitaxel formulation. , 2006, Biomaterials.

[19]  Si-Shen Feng,et al.  Poly(d,l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs. , 2005, Biomaterials.

[20]  M. Rocchetti,et al.  A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation. , 2005, British journal of clinical pharmacology.

[21]  Gérard Hopfgartner,et al.  P‐Glycoprotein and Surfactants: Effect on Intestinal Talinolol Absorption , 2005, Clinical pharmacology and therapeutics.

[22]  J. G. Eley,et al.  Poly (Lactide-co-Glycolide) Nanoparticles Containing Coumarin-6 for Suppository Delivery: In Vitro Release Profile and In Vivo Tissue Distribution , 2004, Drug delivery.

[23]  A. Jemal,et al.  Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. , 2003, Journal of the National Cancer Institute.

[24]  S. Feng,et al.  A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[25]  Kanji Takada,et al.  Enhanced intestinal absorption of vancomycin with Labrasol and D-alpha-tocopheryl PEG 1000 succinate in rats. , 2003, International journal of pharmaceutics.

[26]  Vinod P. Shah,et al.  Biopharmaceutics Classification System: The Scientific Basis for Biowaiver Extensions , 2002, Pharmaceutical Research.

[27]  R. A. Jain,et al.  The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. , 2000, Biomaterials.

[28]  Bruno C. Hancock,et al.  Differential scanning calorimetry: applications in drug development. , 1999, Pharmaceutical science & technology today.

[29]  F. Yuan,et al.  Transvascular drug delivery in solid tumors. , 1998, Seminars in radiation oncology.

[30]  J. Crison,et al.  A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.

[31]  C. F. van der Walle,et al.  Engineering biodegradable polyester particles with specific drug targeting and drug release properties. , 2008, Journal of pharmaceutical sciences.

[32]  B. Yavuz,et al.  Bioavailability File: Exemestane , 2007 .

[33]  C. M. Agrawal,et al.  Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers. , 1996, Biomaterials.

[34]  A. Allen,et al.  Pepsin hydrolysis of the adherent mucus barrier and subsequent gastric mucosal damage in the rat: effect of diosmectite and 16,16 dimethyl prostaglandin E2. , 1994, Gastroenterologie clinique et biologique.